Activity and Safety of CTLA-4 Blockade Combined with Vaccines in Cynomolgus Macaques

Journal of Immunology

Volumn 171, Issue 11, 2003, Pages 6251-6259

  Keler, Tibor ^a   Halk, Ed ^b   Vitale, Laura ^a   O'Neill, Tom ^a   Blanset, Diann ^a   Lee, Steven ^b,d   Srinivasan, Mohan ^b   Graziano, Robert F ^a   Davis, Thomas ^a,e   Lonberg, Nils ^b   Korman, Alan ^b,c  

^a MEDAREX INC   (United States)

^b Medarex ^*  (United States)

^c Medarex   (United States)

^d DiaDeXus   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; IMMUNOGLOBULIN; MELANOMA VACCINE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; BINDING AFFINITY; CELL LYSATE; CONTROLLED STUDY; CROSS REACTION; DRUG SAFETY; FEMALE; HYBRIDOMA; IMMUNOASSAY; IMMUNOMODULATION; INHIBITION KINETICS; MACACA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE; TUMOR IMMUNITY;

EID: 10744234019     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.171.11.6251     Document Type: Article

References (41)

1. Egen, J. G., M. S. Kuhns, and J. P. Allison. 2002. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat. Med. 3:611.
2. Leach, D. R., M. F. Krummel, and J. P. Allison. 1996. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734.
3. Yang, Y. F., J. P. Zou, J. Mu, R. Wijesuriya, S. Ono, T. Walunas, J. Bluestone, H. Fujiwara, and T. Hamaoka. 1997. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. Cancer Res. 57:4036.
4. Kwon, E. D., A. A. Hurwitz, B. A. Foster, C. Madias, A. L. Feldhaus, N. M. Greenberg, M. B. Burg, and J. P. Allison. 1997. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc. Natl. Acad. Sci. USA 94:8099.
5. + T cell- and IL-2-dependent mechanism. Immunity 11:48.
6. Hurwitz, A. A., A. van Elsas, D. R. Leach, J. Ziskin, J. Villasenor, T. Truong, and J. P. Allison. 1999. Manipulation of T cell activation to generate anti-tumor CTL. In Cytotoxic Cells: Basic Mechanisms and Medical Applications. M. V. Sitkovsky and P. A. Henkart, eds. Lippincott and Williams, Philadelphia, p. 385.
7. Hurwitz, A. A., T. F. Yu, D. R. Leach, and J. P. Allison. 1998. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Natl. Acad. Sci. USA 95:10067.
8. van Elsas, A., A. A. Hurwitz, and J. P. Allison. 1999. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190:355.
9. Kwon, E. D., B. A. Foster, A. A. Hurwitz, C. Madias, J. P. Allison, N. M. Greenberg, and M. B. Burg. 1999. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc. Natl. Acad. Sci. USA 96:15074.
10. Mokyr, M. B., T. Kalinichenko, L. Gorelik, and J. A. Bluestone. 1998. Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice. Cancer Res. 58:5301.
11. Krummel, M. F., and J. P. Allison. 1995. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182:459.
12. June, C. H., J. A. Bluestone, L. M. Nadler, and C. B. Thompson. 1994. The B7 and CD28 receptor families. Immunol. Today 15:321.
13. Sharpe, A. H., and G. J. Freeman. 2002. The B7-CD28 superfamily. Nat. Immunol. 2:116.
14. Tivol, E. A., F. Borriello, A. N. Schweitzer, W. P. Lynch, J. A. Bluestone, and A. H. Sharpe. 1995. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3:541.
15. Waterhouse, P., J. M. Penninger, E. Timms, A. Wakeham, A. Shahinian, K. P. Lee, C. B. Thompson, H. Griesser, and T. W. Mak. 1995. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270:985.
16. Vandenborre, K., S. W. Van Gool, A. Kasran, J. L. Ceuppens, M. A. Boogaerts, and P. Vandenberghe. 1999. Interaction of CTLA-4 (CD152) with CD80 or CD86 inhibits human T-cell activation. Immunology 98:413.
17. Kristiansen, O. P., Z. M. Larsen, and F. Pociot. 2000. CTLA-4 in autoimmune diseases-a general susceptibility gene to autoimmunity? Genes Immun. 1:170.
18. Kouki, T., Y. Sawai, C. Gardine, M.-E. Fisfalen, M.-L. Alegre, and L. J. DeGroot. 2000. CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. J. Immunol. 165:6606.
19. Lonberg N., L. D. Taylor, F. A. Harding, M. Trounstine, K. M. Higgins, S. R. Schramm, C. C. Kuo, R. Mashayekh, K. Wymore, J. G. McCabe, et al. 1994. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 368:856.
20. Morgenstern, J. P., and H. Land. 1990. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18:3587.
21. Villinger, F., P. Bostik, A. Mayne, C. L. King, C. P. Genain, W. R. Weiss, and A. A. Ansari. 2001. Cloning, sequencing, and homology analysis of nonhuman primate Fas/Fas-ligand and co-stimulatory molecule. Immunogenetics 53:315.
22. Fishwild, D. M., S. L. O'Donnell, T. Bengoechea, D. V. Hudson, F. Harding, S. L. Bernhard, D. Jones, R. M. Kay, K. M. Higgins, S. R. Schramm, and N. Lonberg. 1996. High-avidity human IgG κ monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat. Biotechnol. 14:845.
23. Kohler, G., and C. Milstein. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495.
24. van Elsas, A., R. P. Sutmuller, A. A. Hurwitz, J. Ziskin, J. Villasenor, J. P. Medema, W. W. Overwijk, N. P. Restifo, C. J. Melief, R. Offringa, and J. P. Allison. 2001. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J. Exp. Med. 194:481.
25. Horspool, J. H., P. J. Perrin, J. B. Woodcock, J. H. Cox, C. L. King, C. H. June, D. M. Harlan, D. C. St. Louis, and K. P. Lee. 1998. Nucleic acid vaccine-induced immune responses require CD28 costimulation and are regulated by CTLA-4. J. Immunol. 160:2706.
26. Zheng, Y., and M. Monestier. 2003. Inhibitory signal override increases susceptibility to mercury-induced autoimmunity. J. Immunol. 171:1596.
27. Walker L. S., H. E. Wiggett, F. M. Gaspal, C. R. Raykundalia, M. D. Goodall, K. M. Toellner, and P. J. Lane. 2003. Established T cell-driven germinal center B cell proliferation is independent of CD28 signaling but is tightly regulated through CTLA-4. J. Immunol. 170:91.
28. Karandikar, N. J., C. L. Vanderlugt, T. L. Walunas, S. D. Miller, and J. A. Bluestone. 1996. CTLA-4: a negative regulator of autoimmune disease. J. Exp. Med. 184:783.
29. Perrin, P. J., J. H. Maldonado, T. A. Davis, C. H. June, and M. K. Racke. 1996. CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. J. Immunol. 157:1333.
30. Zhu, J., L. Zou, S. Zhu, E. Mix, F. Shi, H. Wang, I. Volkmann, B. Winblad, M. Schalling, and H. Ljunggren. 2001. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade enhances incidence and severity of experimental autoimmune neuritis in resistant mice. J. Neuroimmunol. 115:111.
31. Luhder, F., P. Hoglund, J. P. Allison, C. Benoist, and D. Mathis. 1998. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J. Exp. Med. 187:427.
32. Wang, H. B., F. D. Shi, H. Li, B. J. Chambers, H. Link, and H. G. Ljunggren. 2001. Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis. J. Immunol. 166:6430.
33. + regulatory cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 192:303.
34. + regulatory cells that control intestinal inflammation. J. Exp. Med. 192:295.
35. Metz, D. P., D. L. Farber, T. Taylor, and K. Bottomly. 1998. Differential role of CTLA-4 in regulation of resting memory versus naive CD4 T cell activation. J. Immunol. 161:5855.
36. + thymocytes and peripheral T cells have immune suppressive activity in vitro. Eur. J. Immunol. 31:1247.
37. + regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194:823.
38. + cells: a naturally occurring population of regulatory T cells. Blood 98:2736.
39. + T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J. Exp. Med. 193:1295.
40. Hodi, F. S., M. C. Mihm, R. J. Soifer, F. G. Haluska, M. Butler, M. V. Seiden, T. Davis, R. Henry-Spires, S. MacRae, A. Willman, et al. 2003. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl. Acad. Sci. USA 100:4712.
41. Phan, G. Q., J. C. Yang, R. M. Sherry, P. Hwu, S. L. Topalian, D. J. Schwartzentruber, N. P. Restifo, L. R. Haworth, C. A. Seipp, L. J. Freezer, et al. 2003. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 100:8372.